dr. sznol on unanswered questions with immunotherapy in rcc
Published 5 years ago • 139 plays • Length 1:29Download video MP4
Download video MP3
Similar videos
-
1:02
dr. sznol on immunotherapy in patients with rcc
-
1:15
dr. sznol discusses advancements in immunotherapy for rcc
-
1:05
dr. sznol discusses immunotherapy combinations in rcc
-
1:08
dr. sznol on managing patients beyond initial treatment in melanoma
-
0:50
dr. sznol discusses immunotherapy in non-clear cell renal cancer
-
1:00
dr. sznol on immune-related toxicities in melanoma
-
1:25
dr. sznol on patient selection for combination therapy in mrcc
-
1:02
dr. gupta discusses combination immunotherapy in rcc
-
1:22
dr. sznol discusses the combination of ipilimumab and nivolumab in melanoma
-
1:52
dr. powles on monitoring immunotherapy effects in patients with rcc
-
0:56
dr. sznol on the use of immunotherapy in melanoma
-
1:01
dr. sznol on managing toxicities in treatment of melanoma
-
1:14
dr. jonasch on single-agent pembrolizumab in non-clear cell rcc
-
1:15
dr. mcdermott on single-agent versus combination immunotherapy in rcc
-
1:17
dr. hammers on the future of immunotherapy in rcc
-
1:17
dr. sznol on immunotherapy combinations for the treatment of melanoma
-
1:05
dr. pal on potential tivozanib-based combinations in rcc
-
0:53
dr. mario sznol describes nivolumab in advanced melanoma
-
1:47
dr. sznol on combining nivolumab and ipilimumab for the treatment of advanced melanoma